| Literature DB >> 33314632 |
Judith Desoutter1,2, Cédric Usureau1,2, Valentine Jacob1,2, Delphine Lebon2,3, Alexis Caulier2,3, Cécilia Da Costa2, Amandine Charbonnier3, Magalie Joris3, Jean-Pierre Marolleau2,3, Nicolas Guillaume1,2.
Abstract
A hematopoietic chimerism assay is the laboratory test for monitoring engraftment and quantifying the proportions of donor and recipient cells after hematopoietic stem cell transplantation recipients. Flow cytometry is the reference method for determining the purity of CD3+ cells on the chimerism of selected CD3+ cells. In the present study, we developed a single-step procedure that combines the CD3+ purity assay (using the PCR-based Non-T Genomic Detection Kit from Accumol, Calgary, Canada) and the qPCR chimerism monitoring assay (the QTRACE qPCR assay from Jeta Molecular, Utrecht, the Netherlands). First, for the CD3+ purity assay, we used a PCR-friendly protocol by changing the composition of the ready-to-use reaction tubes (buffer and taq polymerase) and obtained a satisfactory calibration plot (R2 = 0.8924) with a DNA reference scale of 2 ng/μl. Next, 29 samples (before and after CD3 positive selection) were analyzed, the mean cell purity was, respectively, 19.6% ± 6.45 and 98.9% ± 1.07 in the flow cytometry assay; 26.8% ± 7.63 and 98.5% ± 1.79 in the PCR-based non-T genomic detection assay. Our results showed that the CD3+ purity assay using a qPCR kit is a robust alternative to the flow cytometry assay and is associated with time savings when combined with a qPCR chimerism assay.Keywords: T-cell selection; accumol; chimerism; hematopoietic stem cell transplantation; purity assay
Year: 2020 PMID: 33314632 DOI: 10.1111/tan.14168
Source DB: PubMed Journal: HLA ISSN: 2059-2302 Impact factor: 4.513